HomeBUSINESS
BUSINESS

Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race
(Sep.19.2017)

Kenji Matsuyama, Senior Operating Officer, Head of Corporate Strategy & Planning Division, Nichi-Iko
Nichi-Iko Pharmaceutical is set to join the fray in the Japanese follow-on biologics market by rolling out its first biosimilar, which will be the second Remicade (infliximab) biosimilar in Japan, as early as November. The Japanese generic major looks to capitalize on its Japanese PIII data and collaboration with GI/rheumatoid arthritis (RA)-savvy partners to outstrip frontrunner Nippon Kayaku ...
(LOG IN FOR FULL STORY)

News Calendar